...
首页> 外文期刊>Journal of neurointerventional surgery >The safety of anticoagulation in patients with intracranial aneurysms
【24h】

The safety of anticoagulation in patients with intracranial aneurysms

机译:颅内动脉瘤患者抗凝的安全性

获取原文
获取原文并翻译 | 示例
           

摘要

Background: and purpose Little is known about the safety of long-term anticoagulation in patients with unruptured saccular intracranial aneurysms, although case reports of anticoagulation in patients with fusiform and saccular aneurysms have been published. The goal of this study was to estimate the rate of subarachnoid hemorrhage (SAH) due to aneurysm rupture in patients with intracranial saccular aneurysms receiving therapeutic doses of anticoagulation. Methods: This was a retrospective case series of patients with intradural aneurysms receiving therapeutic doses of anticoagulation (defined as a dose that achieves a target INR > 2.0 or the equivalent dose of another anticoagulant). The primary outcome was SAH due to aneurysm rupture while receiving anticoagulation treatment. The rate of SAH due to aneurysm rupture was calculated among patients with aneurysms documented on imaging. Results: 42 patients with 48 intradural aneurysms on anticoagulation were identified. Their mean age was 67 years (range 40-83) and 28 (67%) were women. The mean aneurysm size was 5.163.6 mm and 40 (83%) aneurysms were in the anterior circulation. The mean±SD follow-up was 495±749 days per patient. Twelve patients had their aneurysms coiled, clipped or surgically wrapped before the period of anticoagulation. Three patients had clipping or coiling of their aneurysms during the period of anticoagulation. Six patients had a history of aneurysm rupture prior to anticoagulation, of which two were treated by coiling and four by clipping. Among the 48 aneurysms, 32 were never coiled or clipped prior to anticoagulation. No anticoagulated patients with known aneurysms developed SAH during 57 patient-years of follow-up. The patients with untreated aneurysms had 31 patient-years of follow-up and those who underwent clipping, coiling or surgical wrapping of their aneurysms had 26 patient-years of follow-up while receiving anticoagulation (for a combined total of 57 years of follow up). Conclusions: The risk of aneurysm rupture is not increased in patients receiving systemic anticoagulation. However, these results should be interpreted with caution given the small sample size in this study and the need for a prospective study to confirm these findings.
机译:背景和目的尽管关于梭形和囊状动脉瘤患者抗凝治疗的病例报道已有报道,但对于囊状颅内动脉瘤未破裂的患者长期抗凝治疗的安全性知之甚少。这项研究的目的是评估接受治疗剂量的抗凝治疗的颅内囊状动脉瘤患者因动脉瘤破裂导致的蛛网膜下腔出血(SAH)的发生率。方法:这是一例回顾性病例,研究了硬膜内动脉瘤患者接受治疗剂量的抗凝治疗(定义为达到目标INR> 2.0的剂量或等效剂量的另一种抗凝治疗剂)。主要结果是在接受抗凝治疗时由于动脉瘤破裂导致的SAH。在影像学上记录的动脉瘤患者中,计算了由于动脉瘤破裂而引起的SAH发生率。结果:确定了42例患者的48例硬脑膜内抗凝药物。他们的平均年龄为67岁(40-83岁),女性为28岁(67%)。平均动脉瘤大小为5.16.36毫米,前循环中有40个(83%)动脉瘤。每例患者的平均±SD随访时间为495±749天。在抗凝期之前,十二名患者的动脉瘤被盘绕,夹住或通过手术包裹。在抗凝期间,三名患者的动脉瘤被夹住或缠绕。 6例患者在抗凝之前有动脉瘤破裂的病史,其中2例采用盘绕治疗,4例采用钳夹治疗。在48个动脉瘤中,有32个在抗凝之前从未被盘绕或夹住。在57个患者年的随访中,没有已知动脉瘤的抗凝患者发生SAH。未经治疗的动脉瘤患者接受了31个患者年的随访,接受了抗凝,卷曲或外科包裹的患者接受了抗凝治疗后接受了26个患者年的随访(总共接受了57年的随访) )。结论:接受全身性抗凝治疗的患者不会增加动脉瘤破裂的风险。但是,鉴于本研究的样本量较小且需要进行前瞻性研究以确认这些发现,因此应谨慎解释这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号